Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4R subunit of IL-4 and IL-13
receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema).
NAME

Dupilumab (Dupixent)
APPROVED FOR
Adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those treatments are inadvisable. Dupilumab may be used with or without topical corticosteroids. 
